Pfizer Covid-19 vaccine generates robust antibody response in children, without serious safety issues, company says

Pfizer and its partner BioNTech said Monday that they would file for authorization of their Covid-19 vaccine for use in children after clinical trial results showed encouraging antibody levels in volunteers and side effects similar to those in teens and young adults.